1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Traaseth, N.J.
Shi, L.
Verardi, R.
Veglia, G.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Proc.Natl.Acad.Sci.USA
PNASA6
0040
0027-8424
106
10165
10170
10.1073/pnas.0904290106
19509339
Structure and topology of monomeric phospholamban in lipid membranes determined by a hybrid solution and solid-state NMR approach.
2009
NE
J.Biomol.Nmr
JBNME9
0800
0925-2738
44
195
205
10.1007/s10858-009-9328-9
19597943
A refinement protocol to determine structure, topology, and depth of insertion of membrane proteins using hybrid solution and solid-state NMR restraints.
2009
10.2210/pdb2kb7/pdb
pdb_00002kb7
6150.477
Phospholamban
1
man
polymer
no
no
AMEKVQYLTRSAIRRASTIEMPQQARQNLQNLFINFALILIFLLLIAIIVMLL
AMEKVQYLTRSAIRRASTIEMPQQARQNLQNLFINFALILIFLLLIAIIVMLL
P
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
Bl21de3phi
sample
pln
562
Escherichia coli
562
Escherichia coli
plasmid
pMAL
database_2
pdbx_nmr_software
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Data collection
Database references
Derived calculations
1
0
2009-06-16
1
1
2011-07-13
1
2
2022-03-16
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_software.name
Solution NMR structure of monomeric phospholamban
BMRB
Y
RCSB
2008-11-21
REL
REL
structures with the least restraint violations
200
20
2D 1H-15N HSQC
3D H(CCO)NH
3D C(CO)NH
3D 1H-15N NOESY
2D [1H,15N] PISEMA
2D [1H,15N]SAMPI4
1.5
mM
[U-99% 15N] and [U-99% 13C; U-99% 15N]
%
[U-99% 15N] and [15N-Ala] and [15N-Arg] and [15N-Asn] and [15N-Ile] and [15N-Met] and [15N-Leu] and [15N-Phe] and [15N-Val] and [15N-Ser] and [15N-Gln26,Gln29]
6.0
ambient
K
Authors state that they define the z-axis to be parallel with the bilayer normal. Also, the origin (or in other words, when the z Cartesian coordinate is 0) is defined to be the center of the lipid bilayer.
simulated annealing
1
fewest violations
1.5 mM [U-99% 15N] and [U-99% 13C; U-99% 15N] Phospholamban, 90% H2O/10% D2O
90% H2O/10% D2O
160/1 lipid/protein (mol/mol) [U-99% 15N] and [15N-Ala] and [15N-Arg] and [15N-Asn] and [15N-Ile] and [15N-Met] and [15N-Leu] and [15N-Phe] and [15N-Val] and [15N-Ser] and [15N-Gln26,Gln29] Phospholamban, 100% H2O
100% H2O
Schwieters, C. et al.
refinement
X-PLOR NIH
2.18
Schwieters, C. et al.
data analysis
X-PLOR NIH
2.18
Schwieters, C. et al.
structure solution
X-PLOR NIH
2.18
600
Varian
VNMRS
Varian VNMRS
700
Varian
VNMRS
Varian VNMRS
600
Bruker
DMX
Bruker DMX
ALA
1
n
1
ALA
1
P
MET
2
n
2
MET
2
P
GLU
3
n
3
GLU
3
P
LYS
4
n
4
LYS
4
P
VAL
5
n
5
VAL
5
P
GLN
6
n
6
GLN
6
P
TYR
7
n
7
TYR
7
P
LEU
8
n
8
LEU
8
P
THR
9
n
9
THR
9
P
ARG
10
n
10
ARG
10
P
SER
11
n
11
SER
11
P
ALA
12
n
12
ALA
12
P
ILE
13
n
13
ILE
13
P
ARG
14
n
14
ARG
14
P
ARG
15
n
15
ARG
15
P
ALA
16
n
16
ALA
16
P
SER
17
n
17
SER
17
P
THR
18
n
18
THR
18
P
ILE
19
n
19
ILE
19
P
GLU
20
n
20
GLU
20
P
MET
21
n
21
MET
21
P
PRO
22
n
22
PRO
22
P
GLN
23
n
23
GLN
23
P
GLN
24
n
24
GLN
24
P
ALA
25
n
25
ALA
25
P
ARG
26
n
26
ARG
26
P
GLN
27
n
27
GLN
27
P
ASN
28
n
28
ASN
28
P
LEU
29
n
29
LEU
29
P
GLN
30
n
30
GLN
30
P
ASN
31
n
31
ASN
31
P
LEU
32
n
32
LEU
32
P
PHE
33
n
33
PHE
33
P
ILE
34
n
34
ILE
34
P
ASN
35
n
35
ASN
35
P
PHE
36
n
36
PHE
36
P
ALA
37
n
37
ALA
37
P
LEU
38
n
38
LEU
38
P
ILE
39
n
39
ILE
39
P
LEU
40
n
40
LEU
40
P
ILE
41
n
41
ILE
41
P
PHE
42
n
42
PHE
42
P
LEU
43
n
43
LEU
43
P
LEU
44
n
44
LEU
44
P
LEU
45
n
45
LEU
45
P
ILE
46
n
46
ILE
46
P
ALA
47
n
47
ALA
47
P
ILE
48
n
48
ILE
48
P
ILE
49
n
49
ILE
49
P
VAL
50
n
50
VAL
50
P
MET
51
n
51
MET
51
P
LEU
52
n
52
LEU
52
P
LEU
53
n
53
LEU
53
P
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
P
P
O
H
LEU
PHE
32
36
1.59
2
P
P
O
H
ALA
ILE
37
41
1.55
3
P
P
O
H
SER
ARG
11
15
1.57
3
P
P
O
H
ALA
ILE
37
41
1.60
6
P
P
O
H
LEU
PHE
32
36
1.56
6
P
P
O
H
ARG
SER
14
17
1.58
7
P
P
O
H
LEU
PHE
32
36
1.60
11
P
P
HD22
HD22
ASN
ASN
31
35
1.31
14
P
P
H3
H
ALA
MET
1
2
1.32
15
P
P
O
H
ALA
ILE
37
41
1.60
16
P
P
O
H
SER
ARG
11
15
1.58
18
P
P
O
H
LEU
PHE
32
36
1.58
1
P
LYS
4
55.44
-3.68
1
P
ILE
19
-34.78
-28.21
2
P
PRO
22
-30.07
129.75
3
P
PRO
22
-27.35
131.63
3
P
ARG
26
-62.84
-74.68
4
P
MET
21
-90.75
-71.11
4
P
PRO
22
-66.71
-87.46
4
P
GLN
23
-155.67
-79.24
4
P
GLN
24
-62.96
0.27
5
P
MET
21
-99.42
-69.53
5
P
PRO
22
-64.39
-85.50
5
P
GLN
23
-155.43
-82.11
5
P
GLN
24
-69.22
8.87
6
P
ARG
15
-41.18
-19.00
6
P
SER
17
-76.15
-81.55
6
P
GLU
20
-177.83
-124.59
6
P
MET
21
-160.49
-53.87
6
P
PRO
22
-97.07
-76.43
6
P
GLN
23
-127.39
-133.29
7
P
LYS
4
53.56
-0.99
7
P
ILE
19
-35.40
-27.63
8
P
MET
2
-87.46
-94.34
8
P
ILE
19
-34.76
-28.30
9
P
ILE
19
-37.43
-30.33
9
P
PRO
22
-37.70
124.73
10
P
ILE
19
-43.14
-19.16
10
P
GLU
20
-133.09
-65.26
10
P
MET
21
-175.75
113.09
11
P
ILE
19
-36.05
-28.83
11
P
PRO
22
-98.27
-98.49
11
P
GLN
23
-158.46
-17.63
12
P
MET
2
-32.84
-34.83
12
P
ILE
19
-37.09
-23.84
12
P
GLU
20
-146.59
-57.50
12
P
MET
21
178.98
117.77
13
P
SER
17
-72.52
-77.65
13
P
ILE
19
3.81
115.40
13
P
GLU
20
4.89
94.64
13
P
GLN
23
-163.68
-34.38
14
P
PRO
22
-36.97
124.11
14
P
ARG
26
-65.42
-76.90
15
P
ILE
19
-35.95
-29.53
15
P
PRO
22
-39.89
125.25
16
P
ARG
26
-64.94
-75.00
17
P
ILE
19
4.24
112.41
17
P
GLU
20
-20.51
82.07
17
P
GLN
23
-159.87
-43.56
18
P
ILE
19
2.37
114.58
18
P
GLU
20
-1.02
92.13
18
P
PRO
22
-44.75
-70.98
18
P
GLN
23
-166.32
-25.42
19
P
ILE
19
-38.91
-26.83
19
P
PRO
22
-38.58
122.81
20
P
ILE
19
3.18
110.93
20
P
GLU
20
2.57
-100.13
20
P
MET
21
2.08
75.01
20
P
GLN
23
-156.73
-26.31
20
P
GLN
24
-104.61
-71.97
Y
Hybrid solution and solid-state NMR structure of monomeric phospholamban in lipid bilayers
1
N
N
P
LYS
4
A
LYS
4
HELX_P
P
ILE
19
A
ILE
19
1
1
16
P
GLN
24
A
GLN
24
HELX_P
P
LEU
53
A
LEU
53
1
2
30
MEMBRANE PROTEIN
phospholamban, PISEMA, hybrid method, lipid bilayers, topology, MEMBRANE PROTEIN
2KB7
PDB
1
2KB7
1
53
2KB7
1
53
2KB7
P
1
1
53